---
title: "A Study of DIA:CONN P8 Smart Insulin Pen With CGM-Based Coaching in Patients With Type 1 or Type 2 Diabetes"
nct_id: NCT07004153
overall_status: NOT_YET_RECRUITING
phase: NA
sponsor: G2e Co., Ltd
study_type: INTERVENTIONAL
primary_condition: Diabetes Mellitus
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07004153.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07004153"
ct_last_update_post_date: 2025-06-04
last_seen_at: "2026-05-12T07:11:16.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Study of DIA:CONN P8 Smart Insulin Pen With CGM-Based Coaching in Patients With Type 1 or Type 2 Diabetes

**Official Title:** A Multicenter, Open Label, Randomized, Comparative Confirmatory Study to Evaluate the Efficacy and Safety of Electric Smart Insulin Pen (DIA:CONN P8) Including Setup Wizard, Advanced Insulin Injection Coaching and Bolus Calculator With Analysis Function Based on Continuous Glucose Monitoring Data in Patients With Type 1 or Type 2 Diabetes Mellitus Under Multiple Dose Insulin Therapy

**NCT ID:** [NCT07004153](https://clinicaltrials.gov/study/NCT07004153)

## Key Facts

- **Status:** NOT_YET_RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 152
- **Lead Sponsor:** G2e Co., Ltd
- **Conditions:** Diabetes Mellitus
- **Start Date:** 2025-06
- **Completion Date:** 2026-12
- **CT.gov Last Update:** 2025-06-04

## Brief Summary

A Study of DIA:CONN P8 Smart Insulin Pen With CGM-Based Coaching in Patients With Type 1 or Type 2 Diabetes

## Detailed Description

This study evaluates the efficacy and safety of the DIA:CONN P8, an electric smart insulin pen equipped with a Setup Wizard, CGM-based insulin injection coaching, and a bolus calculator. The device is designed to support patients with type 1 or type 2 diabetes who are on multiple daily insulin injections (MDI). The study compares the outcomes of patients using these advanced features to those using only the injection and recording functions of the device.

The rationale stems from previous research showing that structured education in combination with CGM improves glycemic control in patients with diabetes. The DIA:CONN P8 aims to replicate the benefits of such structured education through app-based coaching and algorithm-driven recommendations, potentially reducing the burden of complex insulin dose calculations in routine care.

Participants will undergo a run-in period using DIA:CONN P8 with injection-only functionality to assess compliance. Eligible subjects will then be randomized into either the investigational group (using all device functions) or the control group (injection and recording only). Over 12 weeks, the primary endpoint is the change in HbA1c. Secondary outcomes include CGM-based metrics such as Time in Range (TIR), Time Below Range (TBR), and insulin dosing behavior.

The study is designed as a multicenter, open-label, randomized, comparative confirmatory trial conducted at six sites. A total of 152 subjects will be enrolled.

## Eligibility

- **Minimum age:** 19 Years
- **Maximum age:** 75 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Age between 19 and 75 years old.
2. Diagnosis of type 1 or type 2 diabetes for at least 1 year prior to screening
3. Continuous use of MDI therapy for at least 3 months prior to screening, defined as one of the following regimens:

   * Long-acting insulin plus rapid-/short-acting insulin
   * Mixed insulin (e.g., insulin aspart/insulin degludec) plus rapid-/short-acting insulin
   * Mixed insulin ≥3 times per day
4. HbA1c of 7.5% to 12.0% at screening.

Exclusion Criteria:

1. Diabetes mellitus secondary to pancreatic resection.
2. Use of corticosteroids exceeding a prednisolone-equivalent dose of 5 mg/day within 3 months prior to screening (Subjects on a stable dose for ≥3 months prior to screening may be eligible).
3. eGFR \<15 mL/min at screening or those receiving dialysis
4. Pregnant or lactating women
```

## Arms

- **Investigational Group** (EXPERIMENTAL) — Basal and bolus insulin injection using an electric smart insulin pen (DIA:CONN P8); equipped with a Setup-wizard, CGM-based Advanced insulin injection Coaching and a Bolus calculator

\- Providing education on Carb Counting(carbohydrate measurement) and Methods for adjusting insulin bolus calculator
- **Control group** (NO_INTERVENTION) — Basal and bolus insulin injection using only the injection and recording functions of DIA:CONN P8

\- Subjects manually enter and inject their insulin doses without using the bolus calculator or coaching functions

## Interventions

- **Smart Coaching Insulin Pen** (DEVICE) — Subjects randomized to the intervention group will use the DIA:CONN P8 smart insulin pen with full functionality, including Setup Wizard, CGM-based insulin injection coaching, and a bolus calculator. During the 12-week application period, including the baseline visit, participants will visit the hospital up to 5 times. At the start of the period, initial basal and bolus doses will be determined using the Setup Wizard and reviewed by investigators. Throughout the study, subjects will receive real-time insulin dose recommendations and coaching via the DIA:CONN app based on CGM data, carbohydrate input, and insulin dosing history.

## Primary Outcomes

- **Change in HbA1c(%) at 12 weeks compared to baseline** _(time frame: from baseline to the 12-week time point)_ — Descriptive statistics (sample size, mean, standard deviation, median, minimum, and maximum) are provided for the change in HbA1c (%) from baseline to the 12-week time point, stratified by group.

## Locations (1)

- Samsung Medical Center, Seoul, Gangnam-gu, South Korea

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.samsung medical center|seoul|gangnam-gu|south korea` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07004153.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07004153*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*